A study in humans demonstrated that the miR-6772-3p was selected for validation from RNA-seq data based on an area under the curve greater than 0.6 or involvement in plaque rupture/erosion mechanisms, but it showed no significant difference between plaque rupture and plaque erosion groups in the replication cohort [Li et al. DOI:10.1016/j.ygeno.2020.11.019]. A study in humans identified the miR-6772-3p as a potential biomarker for coronary artery disease, where it was found to be downregulated in patient plasma compared to normal coronary artery controls using RNA sequencing [Zhong et al. DOI:10.1002/jcla.23020].